EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity

Yatian Yang, Xiong Zhang, Varadha Balaji Venkadakrishnan, Hongye Zou, Xingling Zheng, Shiyao Guo, Christopher Z Chen, Alexander D Borowsky, Eva Corey, Ronald M Evans, Allen C Gao, Marc A Dall'Era und 6 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci200260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yatian Yang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Medicine, School of Medicine, UCD, Sacramento, California, USA. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, beta Catenin, Wnt Signaling Pathway, Chromatin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PRC2/EZH2 inhibitors (PRC2i/EZH2i) are promising for the treatment of advanced cancers including metastatic prostate cancer. Here, we show that PRC2i/EZH2i alone or in combination with androgen receptor (AR) inhibitors induced diverse cell state programs (CSPs) (e.g., response to stress or IFN, MYC targets, stem cells, EMT lineage plasticity, and multiple developmental programs), which led to increased tumor cell invasion, metastasis, and resistance to other drugs, in addition to modest suppression of tumor growth. In contrast to the current perception, our comprehensive, integrated genomics and epigenomics profiling of patient-derived xenografts (PDXs) and clinical tumors revealed that PRC2/EZH2 suppressed CSP genes by maintaining chromatin bivalency. Hyperactive Wnt/β-catenin signaling and inhibitors of polycomb-repressive complex 2/enhancer of zeste homolog 2 (PRC2/EZH2) and the AR alter chromatin bivalency through antagonism of PRC2 and stimulation of MLL2/KMT2B in a feed-forward manner. The circadian rhythm regulator REV-ERBα unexpectedly reprogrammed β-catenin in promoting bivalency resolution and CSP gene expression. Dual targeting of Wnt/β-catenin and EZH2 diminished diverse cell states by restoring bivalency and effectively blocked tumor growth. Our findings provide unexpected insights into chromatin bivalency and dysregulated circadian rhythms in the control of cell state diversity and identify alternative therapeutic strategies that target PRC2/EZH2 for advanced malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 Proteinbeta CateninWnt Signaling PathwayChromatinPolycomb Repressive Complex 2Prostatic NeoplasmsNeoplasm ProteinsHumansAnimalsMaleMiceReceptors, AndrogenCell Line, Tumor

Stichwörter der Autor:innen

Cell biologyEpigeneticsGeneticsMolecular biologyOncologyProstate cancer

Substanzen

Enhancer of Zeste Homolog 2 Proteinbeta CateninChromatinPolycomb Repressive Complex 2EZH2 protein, humanNeoplasm ProteinsCTNNB1 protein, humanReceptors, Androgen

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Medicine, School of Medicine, UCD, Sacramento, California, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Pharmaceutical Sciences and Pharmacogenomics (PSPG) Graduate Program, UCSF, San Francisco, California, USA.
  • Department of Pathology and Laboratory Medicine, School of Medicine, UCD, Sacramento, California, USA.
  • Department of Urology, University of Washington, Seattle, Washington, USA.

Förderung

  • NCI NIH HHS
  • BLRD VA
  • NIDDK NIH HHS
  • NIH Office of the Director
  • Prostate Cancer Foundation
  • US Department of Defense-PCRP
  • US Department of Veterans Affairs
  • NIH/NCI Cancer Center Support Grant NCI

Zitieren

APA

Yang, Y., Zhang, X., Venkadakrishnan, V. B., Zou, H., Zheng, X., Guo, S., Chen, C. Z., Borowsky, A. D., Corey, E., Evans, R. M., Gao, A. C., Dall'Era, M. A., Zoubeidi, A., Lara, P. N., Kung, H. J., Chen, X., Beltran, H., & Chen, H. W. (2026). Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity. Journal of Clinical Investigation. https://doi.org/10.1172/jci200260

Vancouver

Yang Y, Zhang X, Venkadakrishnan VB, Zou H, Zheng X, Guo S, et al. Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity. Journal of Clinical Investigation. 2026. doi:10.1172/jci200260

BibTeX
@article{Yang2026,
  author = {Yang, Yatian and Zhang, Xiong and Venkadakrishnan, Varadha Balaji and Zou, Hongye and Zheng, Xingling and Guo, Shiyao and Chen, Christopher Z and Borowsky, Alexander D and Corey, Eva and Evans, Ronald M and Gao, Allen C and Dall'Era, Marc A and Zoubeidi, Amina and Lara, Primo N and Kung, Hsing-Jien and Chen, Xinbin and Beltran, Himisha and Chen, Hong-Wu},
  title = {Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci200260}
}
Kostenlos starten →